0001104659-20-032487.txt : 20200312 0001104659-20-032487.hdr.sgml : 20200312 20200312161201 ACCESSION NUMBER: 0001104659-20-032487 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200310 FILED AS OF DATE: 20200312 DATE AS OF CHANGE: 20200312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myles Edward H CENTRAL INDEX KEY: 0001358219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 20708900 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20070724 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 4 1 a4.xml 4 X0306 4 2020-03-10 0 0000792977 AMAG PHARMACEUTICALS, INC. AMAG 0001358219 Myles Edward H C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET WALTHAM MA 02451 0 1 0 0 COO & CFO Common Stock 2020-03-10 4 A 0 30000 A 98659 D Stock Option (Right to Buy) 7.27 2020-03-10 4 A 0 45000 A 2030-03-10 Common Stock 45000 45000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021. Not applicable. Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. /s/ Joseph Vittiglio, attorney-in-fact 2020-03-12